MiMedx Group Inc (MDXG)
9.22
+0.16
(+1.77%)
USD |
NASDAQ |
Nov 21, 16:00
9.215
0.00 (0.00%)
After-Hours: 20:00
MiMedx Group Revenue (Quarterly): 84.06M for Sept. 30, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 84.06M |
| June 30, 2024 | 87.21M |
| March 31, 2024 | 84.71M |
| December 31, 2023 | 86.83M |
| September 30, 2023 | 81.71M |
| June 30, 2023 | 81.26M |
| March 31, 2023 | 71.68M |
| December 31, 2022 | 74.38M |
| September 30, 2022 | 67.69M |
| June 30, 2022 | 66.88M |
| March 31, 2022 | 58.89M |
| December 31, 2021 | 50.81M |
| September 30, 2021 | 63.07M |
| June 30, 2021 | 68.16M |
| March 31, 2021 | 59.97M |
| December 31, 2020 | 68.55M |
| September 30, 2020 | 64.30M |
| June 30, 2020 | 53.65M |
| March 31, 2020 | 61.74M |
| December 31, 2019 | 76.40M |
| September 30, 2019 | 88.86M |
| June 30, 2019 | 67.44M |
| March 31, 2019 | 66.56M |
| December 31, 2018 | 92.59M |
| September 30, 2018 | 86.96M |
| Date | Value |
|---|---|
| June 30, 2018 | 95.42M |
| March 31, 2018 | 84.15M |
| December 31, 2017 | 87.55M |
| September 30, 2017 | 84.57M |
| June 30, 2017 | 76.41M |
| March 31, 2017 | 72.61M |
| December 31, 2016 | 46.57M |
| September 30, 2016 | 64.43M |
| June 30, 2016 | 57.34M |
| March 31, 2016 | 53.37M |
| December 31, 2015 | 51.84M |
| September 30, 2015 | 49.02M |
| June 30, 2015 | 45.68M |
| March 31, 2015 | 40.77M |
| December 31, 2014 | 39.57M |
| September 30, 2014 | 33.52M |
| June 30, 2014 | 25.57M |
| March 31, 2014 | 19.56M |
| December 31, 2013 | 17.99M |
| September 30, 2013 | 16.12M |
| June 30, 2013 | 13.51M |
| March 31, 2013 | 11.56M |
| December 31, 2012 | 10.51M |
| September 30, 2012 | 7.954M |
| June 30, 2012 | 4.884M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
50.81M
Minimum
Dec 2021
87.21M
Maximum
Jun 2024
70.60M
Average
68.36M
Median
Revenue (Quarterly) Benchmarks
| CEL-SCI Corp | -- |
| AIM ImmunoTech Inc | 0.035M |
| IGC Pharma Inc | 0.412M |
| NovaBay Pharmaceuticals Inc | 2.441M |
| Protalix BioTherapeutics Inc | 17.96M |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | 8.095M |
| Total Expenses (Quarterly) | 72.60M |
| EPS Diluted (Quarterly) | 0.05 |
| Enterprise Value | 1.285B |
| Gross Profit Margin (Quarterly) | 81.77% |
| Profit Margin (Quarterly) | 9.63% |
| Earnings Yield | 6.67% |
| Operating Earnings Yield | 4.65% |
| Normalized Earnings Yield | 6.683 |